Jessie Fang is a partner at Jingtian & Gongcheng.

She earned her LL.B. degree from Fudan University and her LL.M. degree from Harvard University. Jessie’s practice focuses on mergers and acquisitions, outbound investment, foreign direct investment, private equity and venture capital financing, as well as general corporate services.

With over a decade of experience, Jessie has represented a variety of multinational corporations and Chinese enterprises in both domestic and international financing, capital operations, and other commercial activities. She has led mergers and acquisitions across diverse industries, including automotive, consumer goods, renewable energy, exhibitions, healthcare, semiconductors, chemicals, and construction engineering. Through these M&A transactions, she has adeptly represented both buyers and sellers, bringing a balanced perspective to her work.  Committed to supporting Chinese companies in their global endeavors, she also regularly advises investment institutions and industrial enterprises on outbound investment matters, including corporate financing and operations in regions such as Europe, North America, Southeast Asia, and Australia, particularly within the energy, minerals, biomedicine, and private equity sectors.  On the flip side, she also acts for numerous international investors in their greenfield investments and joint ventures in China, providing comprehensive legal support that addresses issues related to land and factory matters, bank financing, labor relations, intellectual property, commercial transactions, regulatory compliance, and shareholder disputes. Recently, she has especially focused on assisting foreign investors with their divestments in China.

Additionally, Jessie has extensive experience in private equity and venture capital, offering comprehensive legal solutions for fundraising, investment, management, and exit strategies to institutional clients, while also providing entrepreneurs and emerging enterprises with general legal services in structuring, financing, and compliance.

Before joining Jingtian & Gongcheng, Jessie was in charge of risk control and compliance for the venture arm of a leading Hong Kong-listed biopharmaceutical group. In this role, she oversaw the structuring, fundraising, domestic and foreign investments, daily operations, and regulatory compliance of the funds. Throughout her tenure, the investment deals and proposed transactions she has led and participated in have spanned Greater China, Southeast Asia, and the United States, involving various innovative therapeutics and the upstream and downstream supply chain of biomedicine. Prior to this position, she practiced law for nearly a decade at two prominent law firms.

Jessie is qualified to practice law in China and is admitted to practice law in New York State, U.S. She is fluent in both Chinese and English.

Education

Master of Laws, Harvard University

Bachelor of Laws, Fudan University

 

Experience

Partner, Jingtian & Gongcheng 

Chief Compliance Officer, Innovent Biologics-sponsored InnoPinnacle Fund

Attorney-at-law, AllBright Law Offices

Legal Counsel (Secondee), Electrolux China

 

Admissions

Lawyers License People's Republic of China

New York State Bar

AMAC Fund Practitioner Qualification

Acted as the China counsel for Joyson Safety Systems (JSS), a global auto safety system supplier, in its acquisition of Takata, a famous Japanese automotive parts company, for more than US$1.5 billion, negotiated with major Chinese OEMs on waivers and indemnification arrangements in the Takata acquisition, and advised JSS on China legal issues in its US$1.2 billion financing deal for the Takata acquisition

Acted as the China counsel for the then shareholders of Key Safety Systems (KSS) (the predecessor of JSS) in Ningbo Joyson Electronic Corp.’s acquisition of KSS for around US$1 billion

Represented ATC Drivetrain, an international auto remanufacturer, in its partial acquisition of a Chinese industry player, and continued acting for ATC Drivetrain in its joint venture with the remaining Chinese shareholders

Represented Sethness, a leading food additive supplier, in its divestments in China as part of the global acquisition of Sethness by Roquette Frères, a French food ingredient company, with a deal value of around US$0.2 billion

Represented SunEdison, the world’s former largest new energy company, in its acquisition of several new energy projects in China, with a total deal value of around RMB 1 billion

Represented Bureau Veritas, a leading international testing service group, in its acquisition of several Chinese construction service companies, with a total deal value of around RMB 1 billion

Represented J-TECH, a PRC listed company, in its indirect acquisition of Yada Electronics, a leading consumer electronics group

Represented UBM (later acquired by Informa Markets), a leading international exhibitions organizer, in its acquisition or proposed acquisition of several exhibitions in China

Represented TBEA, a global energy service provider, in its acquisition or proposed acquisition of domestic and overseas new energy projects

Represented Elementis, an international petrochemical group, in its divestment in Zhejiang, China

Acted for Dynasol, a global leading petrochemical conglomerate, on all legal matters relating to its two JVs in China with a total investment of more than RMB1 billion, including attending board meetings over the years, handling shareholders’ disputes, securing credit lines of more than RMB1 billion for the two JVs from banks in forms of syndicated loans, working capital loans, etc., negotiating land grant contracts and industrial park entry contracts with local governments, etc.

Acted for KSS, a global auto part provider, on all legal matters relating to its JV in Shanghai with a Chinese listed state-owned conglomerate, including equity transfer, plant relocation, non-compete disputes between shareholders, IP license, employment, etc., and also advised KSS on all legal issues relating to the expansion of its wholly-owned plant in Huzhou, China

Represented numerous international and domestic PE/VC funds in equity investments and acquisitions, and continued advising them on portfolio management and divestments in a wide range of industries including biotech/healthcare, consumer goods, financial and commercial services, TMT, green technology, new energy, etc.; the main investors represented over the years include the VC arm of Innovent Biologics, CITIC Capital, China Merchants Capital, Capital Today, Cathay Capital, CDIB Capital, Olympus Capital, Lightspeed, DT Capital, Manulife-sinochem, Sky9 Capital, STIC Investments, Shanghai Pudong Innotek Capital and some other Chinese state-owned venture funds

Acted for various start-up companies in receiving investments, restructuring, or trade sales; most recent representative clients in different sectors include SNH48 (a famous Chinese girl idol group), DeepMotion (an AI tech company, acquired by Xiaomi Corporation), Huzhou Shenke Biotechnology (a leading quality control solution provider for biological products), Halo Top China (an ice cream brand licensed from the US), etc.